Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 1998

View Archived Issues

IL-4(38-37)-PE38KDEL treatment results in complete regression of human glioblastoma tumors

Company Profile: Prolifix

PSA is a useful indicator of prostate cancer in finasteride-treated patients

Roche: half-year 1998 highlights

EntreMed signs CRADA with NCI to advance Endostatin protein studies

FDA clears new product for facilitating GTR procedures

NCI to sponsor pivotal phase III trials of AEterna's Neovastat

MedImmune and Chiron enter agreement on vaccine adjuvant technology

Pacific Pharmaceuticals initiates NCI-sponsored trial at Duke University Medical Center

Phase IIb trial results confirm efficacy and safety of INKP-100 for colonoscopy

Ixion's method of producing islet cells to be covered by U.S. patent

Anergen in-licenses MHC II-peptide complex with potential applications in MS

Novel antiinflammatory azulenes disclosed by Kotobuki

Japan Energy presents new HIV protease inhibitors

Meiji Seika's new macrolides active against Gram-positive microorganisms

Pfizer identifies glycogen phosphorylase inhibitor as potent antidiabetic agent

Preparation and antibacterial activity of new cephems disclosed by Otsuka

Sankyo patents series with dual NK1/NK2-antagonist activity

International team reports discovery of novel immunostimulants

Orion receives EU approval to market Parkinson's disease treatment

Another treatment option added to the anti-HIV arsenal: efavirenz gets FDA approval

Bayer strengthens diagnostics division with acquisition of Chiron subsidiary

New cardioprotectant from RPR shows potential in treating acute myocardial infarction

Infasurf product launch delayed again

ACAT inhibitor synthesized at Slovakofarma and presented at EFMC symposium

Cognition enhancer on the clinical track at Dainippon

Shareholders approve acquisition; AVI BioPharma up and running

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...